Literature DB >> 29262267

Tobacco Smoking Is a Medical Problem. We Ought to Treat It Like One.

Ravi Kalhan1,2, John T Wilkins2,3, Brian L Hitsman2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29262267      PMCID： PMC6020411          DOI： 10.1164/rccm.201711-2354ED

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN： 1073-449X            Impact factor:   21.405


× No keyword cloud information.
  13 in total

1.  Design considerations in an active medical product safety monitoring system.

Authors:  Joshua J Gagne; Bruce Fireman; Patrick B Ryan; Malcolm Maclure; Tobias Gerhard; Sengwee Toh; Jeremy A Rassen; Jennifer C Nelson; Sebastian Schneeweiss
Journal:  Pharmacoepidemiol Drug Saf       Date:  2012-01       Impact factor: 2.890

Review 2.  Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis.

Authors:  Sonal Singh; Yoon K Loke; John G Spangler; Curt D Furberg
Journal:  CMAJ       Date:  2011-07-04       Impact factor: 8.262

Review 3.  Nicotine receptor partial agonists for smoking cessation.

Authors:  Kate Cahill; Nicola Lindson-Hawley; Kyla H Thomas; Thomas R Fanshawe; Tim Lancaster
Journal:  Cochrane Database Syst Rev       Date:  2016-05-09

4.  Cardiovascular and Neuropsychiatric Events after Varenicline Use for Smoking Cessation.

Authors:  Andrea S Gershon; Michael A Campitelli; Steven Hawken; Charles Victor; Beth A Sproule; Paul Kurdyak; Peter Selby
Journal:  Am J Respir Crit Care Med       Date:  2018-04-01       Impact factor: 21.405

5.  Association between hospitalization for pneumonia and subsequent risk of cardiovascular disease.

Authors:  Vicente F Corrales-Medina; Karina N Alvarez; Lisa A Weissfeld; Derek C Angus; Julio A Chirinos; Chung-Chou H Chang; Anne Newman; Laura Loehr; Aaron R Folsom; Mitchell S Elkind; Mary F Lyles; Richard A Kronmal; Sachin Yende
Journal:  JAMA       Date:  2015-01-20       Impact factor: 56.272

6.  Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial.

Authors:  Nancy A Rigotti; Andrew L Pipe; Neal L Benowitz; Carmen Arteaga; Dahlia Garza; Serena Tonstad
Journal:  Circulation       Date:  2010-01-04       Impact factor: 29.690

Review 7.  Pharmacological interventions for smoking cessation: an overview and network meta-analysis.

Authors:  Kate Cahill; Sarah Stevens; Rafael Perera; Tim Lancaster
Journal:  Cochrane Database Syst Rev       Date:  2013-05-31

Review 8.  Varenicline and Adverse Cardiovascular Events: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Authors:  Lee H Sterling; Sarah B Windle; Kristian B Filion; Lahoud Touma; Mark J Eisenberg
Journal:  J Am Heart Assoc       Date:  2016-02-22       Impact factor: 5.501

9.  Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial.

Authors:  Robert M Anthenelli; Neal L Benowitz; Robert West; Lisa St Aubin; Thomas McRae; David Lawrence; John Ascher; Cristina Russ; Alok Krishen; A Eden Evins
Journal:  Lancet       Date:  2016-04-22       Impact factor: 79.321

Review 10.  Risk of cardiovascular serious adverse events associated with varenicline use for tobacco cessation: systematic review and meta-analysis.

Authors:  Judith J Prochaska; Joan F Hilton
Journal:  BMJ       Date:  2012-05-04
View more
  2 in total

Review 1.  Prevention and Treatment of Tobacco Use: JACC Health Promotion Series.

Authors:  Sara Kalkhoran; Neal L Benowitz; Nancy A Rigotti
Journal:  J Am Coll Cardiol       Date:  2018-08-28       Impact factor: 24.094

2.  Cardiovascular Safety of Varenicline, Bupropion, and Nicotine Patch in Smokers: A Randomized Clinical Trial.

Authors:  Neal L Benowitz; Andrew Pipe; Robert West; J Taylor Hays; Serena Tonstad; Thomas McRae; David Lawrence; Lisa St Aubin; Robert M Anthenelli
Journal:  JAMA Intern Med       Date:  2018-05-01       Impact factor: 21.873
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.